Baxter International BAX Injectables & Anesthesia — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Baxter International's injectables & anesthesia — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Baxter International's injectables & anesthesia — net sales?
- Baxter International (BAX) reported injectables & anesthesia — net sales of $301M in Q1 2026.
- How has Baxter International's injectables & anesthesia — net sales changed year-over-year?
- Baxter International's injectables & anesthesia — net sales decreased by 10.1% year-over-year, from $335M to $301M.
- What is the long-term trend for Baxter International's injectables & anesthesia — net sales?
- Over 3 years (2021 to 2025), Baxter International's injectables & anesthesia — net sales has grown at a -0.9% compound annual growth rate (CAGR), from $1.39B to $1.35B.
- What does injectables & anesthesia — net sales mean?
- The total revenue earned from selling injectable drugs and anesthesia products to healthcare providers.
- How do you interpret injectables & anesthesia — net sales?
- An increase indicates growing demand for the company's surgical and critical care pharmaceutical offerings or successful price realization, while a decrease may signal competitive pressure or reduced hospital procedure volumes.
- How does injectables & anesthesia — net sales compare across companies?
- Peers in the medical device and pharmaceutical space typically report this under specialized hospital supply or acute care segments, often benchmarked against broader hospital procedure volume trends.